. . . . . . . "[At the recommended phase II dose (RP2D), patients with clear cell mRCC and one to two prior therapies (including ? 1 VEGF-TKI) were randomized to BNC105P with everolimus (arm A) or everolimus alone (arm B).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:17:14+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .